GS-100
GS-100-A301
Phase 3 gene_therapy active
Quick answer
GS-100 for NGLY1 Deficiency is a Phase 3 program (gene_therapy) at Grace Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Grace Therapeutics
- Indication
- NGLY1 Deficiency
- Phase
- Phase 3
- Modality
- gene_therapy
- Status
- active